Company news
Telix Pharmaceuticals Limited (ASX:TLX) news
Telix Pharmaceuticals Limited news releases on 6ix. Latest, May 10, 2021: Phase III Prostate Cancer Therapy Clinical Trial Commences
Press releases — page 6
Phase III Prostate Cancer Therapy Clinical Trial Commences
May 9, 2021
Activities Report and App 4C for quarter ended 31 March 2021
April 21, 2021
Japanese Renal Cancer Imaging Trial Meets Study Objectives
April 20, 2021
Launch of International NOBLE Registry for SPECT Imaging
April 18, 2021
TGA commences priority evaluation process for Illuccix
April 13, 2021
S&P DJI Announces March 2021 Quarterly Rebalance
March 12, 2021
Appendix 4E - Results for announcement to the market
February 25, 2021
Czech Republic Grants National Authorisation for TLX591 Kit
February 15, 2021
Appendix 4C and Activities Report for December 2020 Quarter
January 28, 2021
New Drug Submission filed with Health Canada for TLX591-CDx
December 15, 2020
IP Agreement with U Southampton for access to TRALA data
December 13, 2020
FDA New Drug Application for TLX591-CDx Proceeds to Review
December 8, 2020
TGA Priority Review Granted for Prostate Cancer Imaging
December 7, 2020
ProstACT Phase III Study Clinical Development Update
December 2, 2020
Briefing for Investor call - TheraPharm GmbH Acquisition
November 30, 2020
Acquisition of TheraPharm GmbH - Investor Call
November 29, 2020
Prostate Cancer Therapy FDA Meeting Update
November 24, 2020
NDA for Prostate Cancer Imaging accepted by US FDA
November 23, 2020
Investor Briefing - Asia Strategy
November 2, 2020
Strategic Licence and Partnership for Greater China Market
November 1, 2020
App 4C and Activities Report for September 2020 Quarter
October 29, 2020
FDA grants Orphan Drug Designation for glioma imaging agent
October 5, 2020
Telix submits NDA to US FDA for Prostate Cancer Imaging
September 23, 2020
Strategic Collaboration with Varian for Prostate Imaging
September 2, 2020
IRE Distribution Partnership for Prostate Cancer Imaging
August 31, 2020
FDA grants orphan drug designation for TLX102
August 30, 2020
Report for half-year to 30 June 2020
August 20, 2020
Appendix 4C and Activities Report - June 2020 quarter
July 26, 2020
Receipt of $11.4M R&D tax rebate
July 21, 2020
FDA grants breakthrough designation for TLX250-CDx product
June 30, 2020
S&P DJI Announces June 2020 Quarterly Rebalance
June 11, 2020
Appendix 4C and Activity Report March 2020 quarter
April 20, 2020
Commercial Distribution Agmt for Prostate Cancer Diagnostic
April 8, 2020
Telix completes acquisition of licensed production facility
April 2, 2020
Telix and partners receive 500k CRC research grant
March 15, 2020
Positive FDA feedback on NDA submission process
February 24, 2020
Appendix 4E - Summary of Results
February 23, 2020
Appendix 4C - December 2019 Quarter
January 28, 2020
Telix Granted FDA Approval for ZIRCON Renal Cancer Imaging
January 22, 2020
NDA Clinical Briefing Package Submitted to the US FDA
December 26, 2019
Zircon P3 IND submitted to US FDA
December 23, 2019
Telix and Vic Cancer Centre receive Cancer Australia grant
December 19, 2019
Telix and ATONCO Partner for Bladder Cancer
December 15, 2019
Telix and AusHealth Partner for Lung, Ovarian Cancer
October 29, 2019
Appendix 4C - September 2019 quarter
October 28, 2019
Telix to Acquire European Production Facility
October 2, 2019
FDA Pre-NDA Meeting Outcomes - TLX591-CDx illumet
August 27, 2019
Appendix 4D and Financial Report for half-year to 30 June 19
August 22, 2019
First Australian Patient Dosed in ZIRCON Phase III Trial
August 20, 2019
Telix Pharmaceuticals announces results of successful SPP
August 19, 2019